CDH2 and glioblastoma: GBM with mesenchymal features (mesenchymal GBM) is characterized by the increased expression of mesenchymal markers (CD44, Vimentin (VIM), N-Cadherin (N-Ca), and ALDH1A3) and a more complex immune-suppressive environment [1].